Stanford University School of Medicine-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2023

  1. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2016

  1. The present and the future of the RAS pathway: From function and genomics to inhibition

    Cancer Biology and Therapy, Vol. 17, Núm. 7, pp. 719-722